Cytokinetics Inc

CYTK

NASDAQ. Currency in USD

50.39 +1.01 ( +2.05% )

Real time prices: October 06

Market Cap.
4.74B
Beta (5Y monthly)
1.05
Price/Earnings
-
EPS (TTM)
-2.56
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
3.28M
1y Target Est.
67.67
Day's Range
48.62
-
52.40
52 Week's Range
29.26
-
55.80

Historical Summary

Performance
EPS growth
Share Buybacks

About Cytokinetics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.cytokinetics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
83.88M
Employees
253
Address
350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Latest news

Cytokinetics Presents New Data From  REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life
By GlobeNewswire Inc. - 4 days ago

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated...
By GlobeNewswire Inc. - 6 days ago

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused...
By GlobeNewswire Inc. - 1 week ago

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on...
By Benzinga - 4 weeks ago

iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here...
By Benzinga - 8 weeks ago

What 5 Analyst Ratings Have To Say About Cytokinetics
What 5 Analyst Ratings Have To Say About Cytokinetics

Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter: Bullish Somewhat...
By Benzinga - 8 weeks ago

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter...
By Zacks Investment Research - 9 weeks ago